Author: Ravi Shankar

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital.

Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme.

The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters and handling of inside information.

The following transactions have been carried out under the programme during the period below:

	Number of shares	Average purchase price	Transaction value in DKK
Treasury shares before start of programme	55.109
Accumulated under the programme in accordance with the latest announcement	8,810	261.16	2,300,818
Monday, 19 October 2026	130	216.00	28,080
Tuesday, 20 October 2026	70	212.00	14,840
Wednesday, 21 October 2026	140	221.86	31,060
Thursday, 22 October 2026	86	230.14	19,792
Friday, 23 October 2026	36	228.00	8,208
Accumulated under the programme in accordance with the above transactions	9.272	233.92	2,402,798

With the above transactions, the company’s holding of treasury shares amounts to 64,381 shares, corresponding to 3.41% of the total number of issued shares of 1,890,000.

Inquiries and further information:
CEO Anders Hedegaard Petersen, phone +45 9630 3117

Appendix

Detailed data on share buy-back transactions is enclosed in accordance with Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, Article 2. All transactions have been carried out by Danske Bank A/S on behalf of Gabriel Holding A/S.

Volume	Price	Venue	Time – GMT	Time – CET
1	216	XCSE	20261019 13:14:35.394665 +0100s	20261019 14:14:35.394665
2	216	XCSE	20261019 14:07:35.818085 +0100s	20261019 15:07:35.818085
127	216	XCSE	20261019 15:46:59.337617 +0100s	20261019 16:46:59.337617
43	212	XCSE	20261020 10:09:59.650608 +0100s	20261020 11:09:59.650608
27	212	XCSE	20261020 10:10:03.363727 +0100s	20261020 11:10:03.363727
50	218	XCSE	20261021 08:02:28.337704 +0100s	20261021 9:02:28.337704
90	224	XCSE	20261021 13:27:27.853531 +0100s	20261021 14:27:27.853531
15	230	XCSE	20261022 08:33:52.746269 +0100s	20261022 9:33:52.746269
10	230	XCSE	20261022 08:33:52.746269 +0100s	20261022 9:33:52.746269
15	230	XCSE	20261022 08:33:52.746269 +0100s	20261022 9:33:52.746269
40	230	XCSE	20261022 11:14:28.612994 +0100s	20261022 12:14:28.612994
2	232	XCSE	20261022 13:54:37.066972 +0100s	20261022 14:54:37.066972
2	232	XCSE	20261022 13:54:37.962842 +0100s	20261022 14:54:37.962842
2	232	XCSE	20261022 13:54:39.060356 +0100s	20261022 14:54:39.060356
36	228	XCSE	20261023 13:24:01.722172 +0100s	20261023 14:24:01.722172

This is a translation of the original Danish text. In the event of discrepancies between the Danish and English texts, the Danish version shall prevail.

Attachment

• Gabriel Holding AS – Announcement no 35 – share buy back week 43

Schindellegi, Switzerland – 26 October 2026

Trifork Group AG
Company announcement no. 64/2026

Weekly report on share buyback

On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026.

Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million).

Under the program, the following transactions have been made:

Date	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Total beginning	578,577	99.95	57,831,397
19 October 2026	2,800	99.20	277,760
20 October 2026	2,900	98.30	285,070
21 October 2026	2,635	98.61	259,837
22 October 2026	2,900	101.11	293,219
23 October 2026	3,000	100.32	300,960
Accumulated	592,812	99.94	59,248,243

A detailed overview of the daily transactions can be found here: https://investor.trifork.com/trifork-shares/.

With the transactions stated above, the total accumulated amount of treasury shares acquired under the current share buyback program corresponds to 3.0% of the share capital of Trifork Group AG. Trifork Group owns 859,228 treasury shares in total, corresponding to 4.4% of the share capital.

Investor & Media contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 7317

About Trifork Group
Trifork (Nasdaq Copenhagen: TRIFOR) is a global technology company specializing in designing, building, and operating advanced software for enterprise and public sector customers. With 1,118 FTEs across 16 countries, Trifork serves as an end-to-end technology partner to organizations in complex and regulated industries, including public administration, healthcare, financial services, energy, and aviation. Learn more at trifork.com.

Attachment

• CA_64_2026_Buyback

TME Pharma extends financial visibility by lengthening debt maturity to June 2028

• Financial visibility extended to second quarter of 2028
• All existing debt holders, including the CEO and two members of the Supervisory Board, are extending the maturity of the debt from May 2027 to 30 June 2028
• €760,000 of debt reimbursed to certain bondholders
• CEO Diede van den Ouden provides a new EUR 250,000 straight bond, without warrants or conversion rights
• Bond financing of EUR 500,000 with Hexagon Capital Fund, to be repaid in cash amortizations

Berlin, Germany, October 26, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company with two assets with potential to be developed into novel therapies for cancer and eye diseases, is pleased to announce that it has extended the maturity of all its outstanding debt by 13 months, from 28 May 2027 to 30 June 2028, and has entered into two new bond financings. Together, these measures extend the Company’s financial visibility to the second quarter of 2028.

By relying on bond financing rather than equity, TME Pharma keeps dilution for its shareholders limited while it continues to pursue value-creating opportunities for its assets.

Several parties have confirmed their support to the Company:

• Diede van den Ouden, CEO, has extended the maturity of his full existing debt to 30 June 2028 and invests an additional EUR 250,000 in a new straight bond maturing on 30 June 2028, without warrants or conversion rights.
• Maurizio PetitBon, Chairman of the Supervisory Board, and Lee Schalop, member of the Supervisory Board, have extended the maturity of their debt to 30 June 2028.
• All other debtholders have extended the maturity of their debt to 30 June 2028 on the same terms. Four external debtholders will receive cash repayments of part of their debt, in an aggregate amount of approximately EUR 760,000, at 97.7% of the nominal value (the contractual early redemption percentage applicable in October 2026). The CEO and the members of the Supervisory Board do not receive any repayment.
• Hexagon Capital Fund subscribes for EUR 500,000 to a bond and will receive 2 million warrants having a strike price of €0.15 with 3 year maturity.

Diede van den Ouden, CEO of TME Pharma, said:         
“I am pleased with the current developments. Since December 2024, we have succeeded in minimizing dilution, allowing the recovery of our market capitalization. Today’s transactions are once again aimed at achieving this goal. I was also eager to invest in a non-dilutive bond myself to directly support this strategy and the corresponding positive momentum.         
We are focused on creating substantial value for our shareholders by advancing favourable terms for a licensing agreement for NOX-A12. With this, we aim to generate cash revenue that will further strengthen TME Pharma’s financial future.         
My interests align with those of all shareholders through the approximately 10 million warrants and options I hold, ensuring that my return is directly linked to our operational success and a sustainably higher share price.”

Financial details

Extension of the existing debt
The holders of all outstanding debt issued by the Company in May and August 2025, representing an aggregate (nominal) loan amount of approximately EUR 2.4 million as of today, have agreed to extend the maturity of their debt from 28 May 2027 to 30 June 2028. The extension has been offered to all debtholders on identical terms. In connection with the extension, the Company will repay in cash part of the debt held by four external debtholders, in an aggregate amount of approximately EUR 760,000, at 97.7% of the nominal value, being the early redemption percentage applicable in October 2026. No repayments are made to the CEO or the members of the Supervisory Board. Following these repayments, the extended debt have an aggregate value of approximately EUR 1.64 million, and approximately EUR 1.96 million at maturity. Upon maturity, the debt will be repaid in cash at 116.5% of their nominal value (which reflects an increase of approximately one percentage point for each additional month, consistent with the existing redemption schedule), unless repaid or contributed to a capital increase earlier. The Company retains the right to repay the debt early in cash at any time, at a percentage of the nominal value that increases monthly in accordance with the applicable redemption table. The debt-holders may require early repayment in the event of a change of control of the Company.

In addition, when a debtholder exercises warrants granted in connection with its debt issued in May or August 2025 and pays the exercise price in full in cash, the debtholder may require the Company to reimburse its debt in cash for an amount equal to 50% of the exercise price received. The Company thus secures both a cash inflow and a reduction of its debt whenever warrants are exercised. The exercise price and maturity of the warrants remain unchanged. The warrants remain in force if the related debt is repaid. Since May 2025, 800,000 shares have been issued from warrant-exercise.

CEO loan
Diede van den Ouden subscribes to a new, non-dilutive, loan with a subscription price of EUR 250,000 and a nominal value of EUR 297,619.05 (issue price of 84% of the nominal value), repayable at 100% of the nominal value on 30 June 2028. The bond bears no interest, it will be repaid in cash. The Company may repay the bond early at any time without penalty, at a percentage of the nominal value that increases in 20 monthly steps from 84% to 100%. The bond carries no warrants and no conversion or other rights to shares, and ranks pari passu with the Company’s other bonds.

Hexagon Capital Fund bond financing
TME Pharma has entered into a bond financing agreement with Hexagon Capital Fund for an initial amount of EUR 500,000. The bonds bear interest at 10% per annum, payable monthly, have a maturity of 24 months and are repaid in cash through amortization instalments per month.

In connection with the financing, the Company grants Hexagon Capital Fund 2,000,000 warrants with an exercise price of EUR 0.15 per share and a term of three years. Full exercise would result in gross proceeds of EUR 300,000 and in the issuance of 2,000,000 new shares, representing approximately 2.1% of the Company’s current share capital of 94,988,981 shares. The exercise price is payable in cash only.
Only in case of an event of default, bonds can only be converted into shares, at a conversion price equal to 85% of the lowest of three daily volume-weighted average prices selected by the holder during the 20 trading days preceding conversion. Any gain realised by Hexagon Capital Fund on the sale of conversion shares in excess of a 15% margin is shared equally with the Company. As the number of shares to be issued upon conversion depends on the share price at that time, a conversion upon default could result in significant dilution for shareholders.

The Company may repay the bonds early at any time without penalty, in cash or, with the consent of Hexagon Capital Fund, in shares, and no security is provided. A structuring fee of 5% of the subscribed amount is payable to Hexagon Capital Fund. At the company’s discretion €1M of further financing is available under the same conditions to provide maximum financial flexibility for the company.

At this time, TME Pharma does not anticipate using this additional financing and its intention is to repay all loans in cash. TME Pharma is currently engaged in concrete discussions regarding a licensing agreement for NOX-A12. One of the objectives of entering into a licensing agreement is to generate cash. TME Pharma will inform the market as soon as the negotiations are concluded.

Corporate approvals
The transactions have been approved by the Management Board and the Supervisory Board. As the CEO and two members of the Supervisory Board are bondholders, the extension of the bonds and the CEO bond were resolved upon by the non-conflicted members of the Management Board and the Supervisory Board, respectively. The warrants are granted under the authorization granted by the general meeting of 25 June 2025.

For more information, please contact:
TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com
www.tmepharma.com

About TME Pharma

TME Pharma is a biotechnology company with two assets with potential to be developed into novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The Company’s two lead assets are:

• NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe.
• NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect.

The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:

• Raising funds from alternative sources to minimize dilution for shareholders
• seeking partners, for example through licensing deals
• Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company
• Leveraging tax loss carry forwards

Further information can be found at: www.tmepharma.com.

About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in combination with radiotherapy and bevacizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nabpaclitaxel in microsatellite-stable metastatic pancreatic cancer patients
The interim financial statements as of and for the six months ended 30 June 2026 of TME Pharma were authorized by the Management Board for issuance on 30 October 2026.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain “forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.

Attachment

• ENG_TME Pharma extends financial visibility by lengthening debt maturity to June 2028

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (ASX: LFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce assay results from the first 5 of 45 drill holes from the Adina-Galinée Lithium Project (“AGLP”) in Québec, Canada (Figure 1). The 45 holes comprise 39 holes totaling 11,420.5 metres completed as part of LIFT’s 2026 summer drilling program, together with 6 previously unreleased historical drill holes from 2024 (1,983 metres), totalling 13,403.5 metres of drill core. Holes ALP-0001 to ALP-0005C from the 2026 drill campaign are presented in this release. The intercepts for drill holes ALP-0001 to ALP-0005C are presented in Table 1 and shown in figures 2, 3 & 4, with a highlight of 56 meters of 1.43 % Li₂O intersected in drillhole ALP002.

Table 1 – Drill intercept from Holes ALP0001 to ALP0005C

Hole No.	From (m)	To (m)	Interval (m)	Li2O%	Zone
ALP0001	201	210	9	1.72	Galinée
ALP0001	357	377	20	0.70	Footwall
ALP0002	187	243	56	1.43	Galinée
ALP0003	257	285	28	1.64	Galinée
ALP0004	52	56	4	1.25	Main
ALP0004	188	201	13	1.29
ALP0004	242	248	6	1.12
ALP0004	285	290	5	0.92	Footwall
ALP0004	296	310	14	0.53
ALP0005C	249	253	4	1.26	Main
ALP0005C	304	308	4	2.61	Main
ALP0005C	342	356	14	1.68	Footwall

Francis MacDonald, President & CEO of LIFT comments,

“We are encouraged by the first results from the 2026 drilling program at Adina-Galinée. The intersections reported today support our interpretation of a large, continuous spodumene-bearing pegmatite system and contribute additional data that will be incorporated into future resource modelling and technical studies. With drilling, ore-sorting test work, geotechnical investigations and property-scale exploration underway, the 2026 program is intended to advance our understanding of the project while evaluating opportunities to further enhance its long-term development potential.”

Figure 1 – Location of LIFT’s spodumene pegmatite properties in Quebec, Canada

The Adina–Galinée spodumene pegmatite is an east–west trending dyke system that dips shallowly to the south at approximately 35°. It comprises three zones: the Main Zone, Footwall Zone and Galinée Zone (Figures 3 and 4). Together, these zones define a low-angle corridor approximately 350 metres wide that strikes for approximately 2.5 kilometres beneath overlying till cover. The 2026 drill program focused primarily on the Galinée Zone (Figures 2 and 3), the least well-defined of the project’s three mineralized structures. Drilling aimed to establish a level of geological understanding comparable to that of the Main and Footwall zones. The results of

Figure 2 – Plan map showing historical drill traces and LIFT’s 2026 drill holes, as well as a level plan of the Adina-Galinée pegmatite complex at 475 m above sea level, approximately 50 m below the surface and 25 m below the bedrock-till interface.

this work will be used to combine the Main, Footwall and Galinée mineralization zones into a Mineral Resource Estimate and Preliminary Economic Assessment, targeted for early 2027⁽¹⁾.

The Adina–Galinée Lithium Project is in the Eeyou Istchee James Bay region of Québec, Canada, a hard-rock lithium district containing several significant spodumene-bearing pegmatite deposits. These include the Shaakichiuwaanaan Project, with mineral reserves of 84.3 Mt at 1.26% Li₂O⁽²⁾; the Moblan Lithium Project, with mineral resources of 121.0 Mt at 1.19% Li₂O⁽³⁾, and the Whabouchi Lithium Project, with mineral resources of 26.9 Mt at 1.45% Li₂O, and ore reserves of 26.5 Mt at 1.32% Li₂O⁽⁴⁾ (Figure 1).

Figure 3 – North–south vertical section through the Adina-Galinée pegmatite complex showing LIFT’s 2026 drill results and historical drill results previously reported to the ASX^{5, 6}. Section trace A-A’ is shown in Figure 2.

Figure 4 – North–south vertical section through the Adina-Galinée pegmatite complex showing LIFT’s 2026 drill results and historical drill results previously reported to the ASX⁷. Section trace B-B’ is shown in Figure 2.

Table 2: Collar information for diamond drill holes presented in this news release.

Drill Hole	NAD83	Easting	Northing	Elevation (m)	Depth (m)	Azimuth (°)	Dip (°)
ALP0001	Zone 18N	668,340	5,908,561	505	399	000	-76
ALP0002	Zone 18N	668,340	5,908,431	502	252	000	-76
ALP0003	Zone 18N	668,340	5,908,487	503	435	000	-76
ALP0004	Zone 18N	668,290	5,908,535	503	377	000	-50
ALP0005C	Zone 18N	668,289	5,908,447	504	387	000	-53

Quality Assurance and Quality Control

All drill core samples were collected under the supervision of LIFT employees and contractors. Drill core was transported from the drill platform to the core processing facility at the Renard Mine, where it was logged, photographed, and split using a diamond saw prior to sampling. Samples were then bagged, and blanks and certified reference materials were inserted at regular intervals. Groups of samples were placed in large bags and sealed with numbered tags to maintain a chain of custody before being transported from LIFT’s Renard core logging facility to MSALABS (“MSA”), a commercial laboratory independent of LIFT, for sample preparation (crushing and pulverizing) and lithium assay.

Samples were prepared for analysis by MSALABS using preparation methods CRU-CPA and PPU-530. Samples were dried in their entirety and crushed to 70% passing 2 mm, and a 500 g subsample was split (CRU-CPA). A 1,000 g sample was pulverized to 85% passing 75 µm (PPU-530). Prepared sample pulps were analyzed using MSALABS’ custom multi-element analytical package PER-700W, involving sodium peroxide fusion of a 0.15 g aliquot followed by inductively coupled plasma atomic emission spectrometry and mass spectrometry (ICP-AES/MS). Lithium concentrations were converted to lithium oxide (Li₂O) using a conversion factor of 2.153.

For further information, please contact:

Francis MacDonald Chief Executive Officer Tel: + 1.604.609.6185 Email: investors@li-ft.com Website: www.li-ft.com	John David MacDougall Investor Relations Manager Tel: +1.604.609.6185 Email: investors@li-ft.com

This release is authorised by the Board of Directors of LIFT.

About LIFT

LIFT is a Canadian lithium exploration and development company focused on advancing its flagship Adina and Galinée Lithium Projects and the Renard processing facility in the Eeyou Istchee James Bay region of Québec. The Company is working toward becoming Canada’s next producer of spodumene concentrate by leveraging its large-scale, high-grade lithium resources and the existing infrastructure at Renard, which LIFT holds under an exclusive option to acquire. LIFT also owns the Yellowknife Lithium Project in the Northwest Territories and maintains additional exploration properties in Canada.

Qualified Person

The disclosure in this news release of scientific and technical information regarding LIFT’s mineral properties has been reviewed and approved by Marc-Antoine Laporte, M.Sc.., P.Geo., Director Geological Services MIN NAM Global, SGS Geological Services who is an independent Qualified Person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects (NI 43-101).

Competent Person’s Statement

Information in this announcement that relates to exploration results is based on and fairly represents information and supporting documentation obtained by LIFT and reviewed and approved by Mr. Marc-Antoine Laporte, M.Sc.., P.Geo., Director Geological Services MIN NAM Global, SGS Geological Services, a Competent Person who is a Member of Ordre des Géologue du Québec (1347). Mr. Laporte has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity which he is undertaking to qualify as a ‘Competent Person’ as defined in the 2012 Edition of the ‘Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves’ (“JORC Code”). Mr. Laporte is an independent consultant with SGS Canada Inc. – SGS Geological Services and Mr. Laporte consents to the inclusion in this announcement of the matters based on this information in the form and context in which it appears.

Past Exploration Results and Mineral Resource estimates reported in this announcement were first reported by the Company in accordance with ASX Listing Rules 5.7 and 5.8 in its Prospectus lodged with ASIC on 13 April 2026 (the “Prospectus”). The Company confirms that it is not aware of any new information or data that materially affects the information included in the Prospectus and that in the case of the Mineral Resource estimates, that all material assumptions and technical parameters underpinning the estimates in the Prospectus continue to apply and have not materially changed. The Company confirms that the form and content in which the Competent Person’s findings are presented here have not been materially modified from the Prospectus. Refer to the Prospectus for further information.

Cautionary Statement Regarding Forward-Looking Information

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matter described in this news release.

Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors” in the Company’s latest annual information form filed on April 27, 2026, which is available under the Company’s SEDAR+ profile at www.sedarplus.ca, in the Company’s prospectus supplement dated August 6, 2026, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

¹ Li-FT Power Ltd., Prospectus 11 August 2026, page 13.
² PMET Resources, ASX announcement PMET Resources Delivers Positive CV5 Lithium-Only Feasibility Study for its Large-Scale Shaakichiuwaanaan Project, 20 October 2025, page 1.
³ Sayona Mining Limited, ASX announcement 25 August 2025, Table 1, page 3.
⁴ Rio Tinto, ASX announcement 4 December 2025 Table C & D, page 7.
⁵ Historical drill intersections starting with “AD” are sourced from Winsome Resources Ltd’s ASX announcement released 28 May 2024.
⁶ Historical intersections starting with “GAL” are sourced from LIFTs Prospectus Annexure C released to the ASX on 22 May 2026.
⁷ Historical drill intersections are sourced from Winsome Resources Ltd’s announcement “Adina Drilling and Operations Update”, released to ASX on 19 August 2024.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/68b4e2cb-8340-403b-9b13-c2d1fdb6ddcd
https://www.globenewswire.com/NewsRoom/AttachmentNg/a16aff63-5747-4ff4-ba61-ac93c10bbc90
https://www.globenewswire.com/NewsRoom/AttachmentNg/e7450ddf-15cc-414b-9e47-83655545d6e6
https://www.globenewswire.com/NewsRoom/AttachmentNg/f78b4fb4-ccd0-4bbb-9417-220f7adde991

Amsterdam, 26 October 2026

EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

Exor N.V. (AMS: EXO) (“Exor” or the “Company”) announces that, under the first tranche of the share buyback program of up to €125 million announced on 23 September 2026 (the “First Tranche”), the Company has completed the following transactions on Euronext Amsterdam, CBOE DXE, Turquoise Europe and Aquis Exchange Europe:

EURONEXT AMSTERDAM

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
19 October 2026	49,835	68.18	3,397,681.50
20 October 2026	49,555	68.26	3,382,840.87
21 October 2026	11,151	68.29	761,488.41
22 October 2026	14,181	67.75	960,767.00
23 October 2026	14,642	67.63	990,239.92
TOTAL	139,364		9,493,017.71

CBOE DXE

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
19 October 2026	33,420	68.14	2,277,244.53
20 October 2026	32,439	68.36	2,217,389.57
TOTAL	65,859		4,494,634.10

TURQUOISE EUROPE

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
19 October 2026	5,892	68.19	401,776.83
20 October 2026	5,953	68.22	406,120.25
TOTAL	11,845		807,897.08

AQUIS EXCHANGE EUROPE

Trading Date	Number of ordinary shares purchased	Average price per share excluding fees (€)	Total consideration excluding fees (€)
19 October 2026	6,919	68.14	471,463.11
20 October 2026	7,043	68.27	480,820.38
TOTAL	13,962		952,283.49

After these purchases, the total invested amount under the first tranche is approximately €125 million for a total amount of 1,795,096 ordinary shares purchased.

With the purchases described above, the Company has completed the first tranche of the share buyback program announced on 23 September 2026.

As of 26 October 2026, the Company held in total 6,833,472 ordinary shares in treasury (3.29% of total ordinary issued share capital)¹.

A comprehensive overview of the transactions carried out under the share buyback program, as well as the details of the above transactions, are available on Exor’s corporate website under the Share Buyback section.

¹ This corresponds to 1.01% of the total issued share capital including both ordinary shares and special voting shares.

Attachment

• Exor Press Release – W44-26 Buyback

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 26 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares	23 October 2026
Number of Shares purchased	10,480 Class A Shares
Highest price/lowest price paid	£14.94 / £14.83
ISIN for the Shares	GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 36,930,837‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 36,930,837 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

Infortar will organize a webinar for investors on 2 November 2026 at 12:00 (EET) in Estonian and at 14:00 (EET) in English to introduce the third quarter 2026 results. The webinar will be attended by the Managing Director Martti Talgre and Investor Relations Manager Kadri Laanvee.

The webinar will be hosted on the Microsoft Teams platform. Please note that to participate, no prior registration is required, and no reminder of the webinar will be sent. You can either participate by joining from your web browser or via Microsoft Teams application. When using a smart device to join the webinar, you first need to download the Microsoft Teams application from either Play Store or App Store.

Please join the webinar via the following links:

2 November at 12:00 (EET) Estonian webinar
2 November at 14:00 (EET) English webinar

Questions can be sent to investor@infortar.ee before the webinar and via Teams Q/A during the event. The webinar will be recorded and will be available online for everyone on the company’s website at https://infortar.ee/en/reports.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.35% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m². In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

26 October 2026

DXS INTERNATIONAL PLC (AQSE: DXSP)

Notice of AGM

DXS International plc (AQSE: DXSP), the UK healthcare technology provider, announces that it has published its Notice of its Annual General Meeting (“AGM”) which will be held at DXS offices at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB on 19th November 2026 at 11.30 a.m.

The Notice of AGM, together with the accounts, have been dispatched to all shareholders.

An electronic copy of the Notice of AGM is also available on the Company’s website:

https://www.dxs-systems.co.uk/corporate-documents.php

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman, CEO

DXS International plc

www.dxs-systems.com

Tel: 01252 719800

AQSE Corporate Broker and Corporate Advisor

Hybridan LLP

Claire Louise Noyce    

Tel: 020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Attachment

• AGM Notice 26 October 2026

Hydro is pleased to invite investors, analysts, financial media and other stakeholders to its Investor Day on November 25, 2026.

The event will be held at 30 Euston Square, London NW1 2FB, with the alternative of joining virtually. Please note that virtual attendees will not have the opportunity to ask questions in the Q&A session.

Agenda
Presentations and Q&A in the Euston room
08:30 Registration
09:00 Presentation from CEO and CFO followed by Q&A sessions
11:30 Lunch
12:30 Roundtable with CEO and CFO, exclusively for sell-side analysts
All times in GMT

Please register your participation by November 3, by submitting the ‘Registration form‘.

Virtual attendees can follow the presentation and Q&A sessions via the webcast.

Hydro looks forward to welcoming you to our Investor Day in London.

Best regards,
for Norsk Hydro ASA

Gerd Aalborg Aas
SVP Group Finance & Investor Relations
+47 91305534
Gerd.Aalborg.Aas@hydro.com

Valentina Gandolfi
Investor Relations Manager
+47 95882355
Valentina.Gandolfi@hydro.com

STMicroelectronics introduces first automotive safety combination sensors for mass-market applications

• Cohesive sensor platform accelerates development of advanced active and passive safety systems
• First mass-market products launched following the integration of NXP’s sensors division earlier this year

Geneva, Switzerland, October 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has announced a set of automotive sensors that enable vehicle brands to extend advanced safety and driver-assistance features across categories from premium to mass-market, broadening access to state-of-the-art protection.

Combining multi-axis accelerometers and gyroscopes (angular rate sensors) in a single package, ST’s new sensors offer a unified platform for OEMs and Tier-1 suppliers to build active and passive safety systems that meet stringent automotive quality, reliability, and safety requirements. The devices address use-cases ranging from crash protection, rollover detection, and airbag deployment to vehicle stability controls and radar beam stabilization.

These are the first products launched in the mass market following ST’s acquisition of the NXP automotive and industrial MEMS sensors business in early 2026, a move completed to expand its own MEMS sensors capabilities. ST’s experience in automotive sensing reflects its commitment to guaranteeing product availability for at least 15 years, allowing companies to minimize lifecycle and redesign risks while investing confidently in new programs.

“As a cohesive sensor set suited to multiple safety functions, these devices simplify system architecture, accelerate development, and increase flexibility to scale features and performance,” said Simone Ferri, Executive Vice President, MEMS Sub-Group, STMicroelectronics. “Strengthened by our longevity commitment and global support infrastructure, these are the first automotive safety combination sensors ready for mass-market deployment, accelerating the move to active safety.”

Omdia has commented on the market opportunities for inertial sensing in Advanced Driver Assistance Systems (ADAS). Nora Houlihan, Senior Research Analyst at Omdia, said, “Thanks to ADAS, inertial measurement units (IMUs) are expected to grow at 17.7% CAGR (2025-30). As automotive manufacturers approach higher levels of autonomy there will be a significant increase in IMU-powered MEMS sensors for acceleration and motion detection.”

Further technical information

ST’s combination sensors integrate a multi-axis accelerometer and gyroscope in a single ISO 26262 compliant device with full internal diagnostics. All sensors support SafeSPI, the standard serial peripheral interface for automotive safety, that enables independent monitoring of sensor data.

The new sensors comprise:

• NCS1012BAEP, with z-axis (yaw) angular rate sensor and xy low g acceleration sensor.
• NCS1012CAEP, with x-axis (roll) angular rate sensor and yz low g acceleration sensor.
• NCS1012EAEP, with x-axis (roll) angular rate sensor and xy medium g acceleration sensor.
• NCS10135AEP with z-axis (yaw) angular rate sensor and xyz low g acceleration sensor.

The integrated angular rate sensors have a full-scale range of ±125 dps, ±250 dps or ±350 dps and feature low offset with minimal drift over the automotive temperature range (−40°C to +105°C). A low-pass filter is integrated, with 3dB frequency options of 12.5Hz to 400Hz, as well as an optional single-pole high-pass filter with fast startup.

The low g acceleration sensors feature a nominal full-scale range from ±1.50 g to ±34 g, while the medium g acceleration sensors have nominal full-scale range from ±15.5 g to ±150 g, featuring an independent signal chain to minimize noise, low offset with low drift over the automotive temperature range, and an integrated low-pass filter.

The four new sensors are in production now, in 24-pin QFN 6mm x 6mm x 1.90mm packages, with wettable flanks meeting automotive-industry optical inspection compatibility requirements.

Contact your local ST sales office for sample requests and pricing.

Please visit www.st.com/mems-for-automotive for more information.

About STMicroelectronics

At ST, we are 49,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com.

For further information, please contact:

INVESTOR RELATIONS
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41 22 929 59 20
jerome.ramel@st.com

MEDIA RELATIONS
Alexis Breton
Group VP Corporate External Communications
Tel: +33 6 59 16 79 08
alexis.breton@st.com

Attachment

• P4796D — Oct 26 2026 — MEMS Safety Sensors_FINAL FOR PUBLICATION